Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diabetic Macular Edema
- Non Proliferative Diabetic Retinopathy
- Proliferative Diabetic Retinopathy
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is an open-label, Phase II comparative study of an intravitreal dexamethasone implant versus intravitreal bevacizumab (Avastin) in 20 patients with recalcitrant diabetic macular edema and prior treatment with ? 2 intravitreal anti-VEGF injections.
This is an open-label, Phase II comparative study of an intravitreal dexamethasone implant versus intravitreal bevacizumab (Avastin) in 20 patients with recalcitrant diabetic macular edema and prior treatment with ? 2 intravitreal anti-VEGF injections.
Tracking Information
- NCT #
- NCT01571232
- Collaborators
- Allergan
- Investigators
- Principal Investigator: Ron P Gallemore, M.D, Ph.D Retina Macula Institute
Get Well Soon